Navigation Links
David S. Tierney, M.D., Joins Thomas, McNerney & Partners as Entrepreneur-In-Residence

David S. Tierney, M.D. joins Connecticut office to Focus on Specialty

Pharmaceuticals, Drug Delivery and Biotechnology

STAMFORD, Conn., April 21 /PRNewswire/ -- Thomas, McNerney & Partners, LLC, a health care venture capital firm that invests in life science and medical technology companies, today announced that David S. Tierney, M.D., has joined as an Entrepreneur-in-Residence in the firm's Connecticut office. Most recently, Dr. Tierney was president and chief executive officer of Valera Pharmaceuticals, Inc., a fully-integrated specialty pharmaceutical and drug delivery company, which was acquired by Indevus Pharmaceuticals.

"David's background is perfect for this role. He has experience as a chief executive with an entrepreneurial company, and also as a drug developer in both specialty and mainstream markets," said Alex Zisson, partner. "We're looking forward to working with David on ideas for new companies and potential investments."

Dr. Tierney has more than 18 years of drug development experience, most recently as chief executive officer of Valera Pharmaceuticals, Inc. Prior to joining Valera, he was president of Biovail Technologies, overseeing all research, development, clinical and regulatory affairs. Prior to Biovail, Dr. Tierney was senior vice president, drug development for Roberts Pharmaceuticals, which was acquired by Shire plc. He began his pharmaceutical career at Elan Corporation where he spent eight years in various drug development roles. Dr. Tierney is also a member of the board of directors of Catalyst Pharmaceuticals Partners, Inc, Nexmed Inc and serves as chairman of the board of directors of Bioject Inc.

"Thomas, McNerney & Partners has a great platform in biopharmaceuticals," said Dr. Tierney. "The partners have many contacts in industry and academia, and I'm confident that I'll be able to add value to their investment process while we work together to identify my next operating role."

About Thomas, McNerney & Partners

Thomas, McNerney & Partners is a health care venture capital firm with approximately $600 million under management focused on investing in life science and medical technology companies at all stages of development. In addition to helping entrepreneurs launch companies with seed and early stage funding, the firm provides growth capital to emerging companies to advance clinical development or for product commercialization. Thomas, McNerney & Partners also is involved in spinning out products and divisions from major medical device and pharmaceutical companies, consolidating companies through roll-up strategies and participating in structured financings for public companies as well as recapitalizations. The firm is targeting investments in the pharmaceutical, medical device, biotechnology and diagnostic sectors and in other areas utilizing medical technology innovation. The firm has offices in Stamford, Minneapolis and San Francisco. For further information, please visit

SOURCE Thomas, McNerney & Partners, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. NSF International Acquires David Begg Associates
2. Former Banc of America Securities Analyst David Maris Comments on Decision by Biovail to Drop Its Claims Against Him; Denies That He is Cooperating With Biovail
3. Morria Biopharmaceuticals Plc Appoints Dr. Johnson Lau and Dr. David Sidransky to Board of Directors
4. David Barker, Former Illumina CSO, Joins GenVaults Scientific Advisory Board
5. Indevus Pharmaceuticals Announces Retirement of David B. Sharrock From Its Board of Directors
6. Dr. David Sidransky Appointed Chairman of Champions Biotechnology, Inc.
7. Immunosyn Corporation Names G. David Criner as CFO
8. Pasteuria Bioscience Taps New CEO David N. Duncan
9. David Mott Appointed Non Executive Director at Shire
10. Stereotaxis Appoints David Burkhardt, M.D. as Chief Medical Officer
11. Transgenomic Appoints David Pauluzzi to Board of Directors
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... ... that includes over 2,000 technical presentations offered in symposia, oral sessions, workshops, awards, ... spectroscopy, covers a wide range of applications such as, but not limited to, ...
(Date:11/26/2015)... , November 26, 2015 /PRNewswire/ ... --> Accutest Research Laboratories, ... Contract Research Organization (CRO), has formed ... Cancer Center - Temple Health for ... ,     (Photo: ) , ...
(Date:11/25/2015)... November 26, 2015 ... Market 2016 - 2020 report analyzes that automating ... and quality in long-term samples, minimizing manual errors, ... Automation minimizes manual errors such as mislabeling or ... Further, it plays a vital role in blood ...
(Date:11/25/2015)... 2 nouvelles études permettent d , identifier ... souches bactériennes retrouvées dans la plaque dentaire des ... Ces recherches  ouvrent une nouvelle voie ... l,un des problèmes de santé les plus fréquemm ... --> 2 nouvelles études permettent d , ...
Breaking Biology Technology:
(Date:11/2/2015)... PARK, Calif. , Nov. 2, 2015  SRI ... $9 million to provide preclinical development services to the ... the contract, SRI will provide scientific expertise, modern testing ... wide variety of preclinical pharmacology and toxicology studies to ... --> The PREVENT Cancer Drug Development ...
(Date:10/29/2015)... -- Connected health pioneer, Joseph C. Kvedar , MD, ... and wellness, and the business opportunities that arise from ... of Healthy Things . Long before health and ... Kvedar, vice president, Connected Health, Partners HealthCare, was creating ... from the hospital or doctor,s office into the day-to-day ...
(Date:10/27/2015)... , Oct. 27, 2015 Synaptics Inc. (NASDAQ: ... today announced that Google has adopted the Synaptics ® ... controller solutions to power its newest flagship smartphones, the ... Huawei. --> --> ... Google to provide strategic collaboration in the joint development ...
Breaking Biology News(10 mins):